Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. more
Time Frame | ALZN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.4% | -3.72% | -0.05% |
1-Month Return | -9.63% | -1.85% | 2.75% |
3-Month Return | -32.97% | -11.4% | 7.4% |
6-Month Return | -69.5% | -4.41% | 10.47% |
1-Year Return | -87.8% | 4.13% | 27.57% |
3-Year Return | -99.68% | 0.3% | 29.56% |
5-Year Return | -99.94% | 36.62% | 89.3% |
Apr '20 | Apr '21 | Apr '22 | Apr '23 | Apr '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Cost of Revenue | - | - | - | 23.07K | 50.74K | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":45.46,"profit":true},{"date":"2024-04-30","value":100,"profit":true}] |
Gross Profit | - | - | - | (23.07K) | (50.74K) | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":-2306600,"profit":false},{"date":"2024-04-30","value":-5074000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Operating Expenses | 4.42M | 4.95M | 12.32M | 14.87M | 9.94M | [{"date":"2020-04-30","value":29.75,"profit":true},{"date":"2021-04-30","value":33.3,"profit":true},{"date":"2022-04-30","value":82.85,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":66.83,"profit":true}] |
Operating Income | (4.42M) | (4.95M) | (12.32M) | (14.87M) | (9.94M) | [{"date":"2020-04-30","value":-442416100,"profit":false},{"date":"2021-04-30","value":-495188800,"profit":false},{"date":"2022-04-30","value":-1231953500,"profit":false},{"date":"2023-04-30","value":-1487046600,"profit":false},{"date":"2024-04-30","value":-993764500,"profit":false}] |
Total Non-Operating Income/Expense | 27.85K | (251.78K) | (89.05K) | (15.40K) | (20.20K) | [{"date":"2020-04-30","value":100,"profit":true},{"date":"2021-04-30","value":-904.04,"profit":false},{"date":"2022-04-30","value":-319.74,"profit":false},{"date":"2023-04-30","value":-55.3,"profit":false},{"date":"2024-04-30","value":-72.54,"profit":false}] |
Pre-Tax Income | (4.41M) | (5.05M) | (12.36M) | (14.88M) | (9.95M) | [{"date":"2020-04-30","value":-441023600,"profit":false},{"date":"2021-04-30","value":-504656700,"profit":false},{"date":"2022-04-30","value":-1236205900,"profit":false},{"date":"2023-04-30","value":-1487816700,"profit":false},{"date":"2024-04-30","value":-994774600,"profit":false}] |
Income Taxes | (13.93K) | 157.10K | 42.52K | (144.83K) | - | [{"date":"2020-04-30","value":-8.86,"profit":false},{"date":"2021-04-30","value":100,"profit":true},{"date":"2022-04-30","value":27.07,"profit":true},{"date":"2023-04-30","value":-92.19,"profit":false},{"date":"2024-04-30","value":"-","profit":true}] |
Income After Taxes | (4.40M) | (5.20M) | (12.40M) | (14.73M) | - | [{"date":"2020-04-30","value":-439631100,"profit":false},{"date":"2021-04-30","value":-520366400,"profit":false},{"date":"2022-04-30","value":-1240458300,"profit":false},{"date":"2023-04-30","value":-1473333800,"profit":false},{"date":"2024-04-30","value":"-","profit":true}] |
Income From Continuous Operations | (4.41M) | (5.05M) | (12.36M) | (14.88M) | (9.95M) | [{"date":"2020-04-30","value":-441023600,"profit":false},{"date":"2021-04-30","value":-504656700,"profit":false},{"date":"2022-04-30","value":-1236205900,"profit":false},{"date":"2023-04-30","value":-1487816700,"profit":false},{"date":"2024-04-30","value":-994774700,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}] |
Net Income | (4.40M) | (5.20M) | (12.40M) | (14.88M) | (9.95M) | [{"date":"2020-04-30","value":-439631100,"profit":false},{"date":"2021-04-30","value":-520366400,"profit":false},{"date":"2022-04-30","value":-1240458300,"profit":false},{"date":"2023-04-30","value":-1487816700,"profit":false},{"date":"2024-04-30","value":-994774600,"profit":false}] |
EPS (Diluted) | (0.07) | (0.06) | (0.14) | (0.15) | (14.21) | [{"date":"2020-04-30","value":-6.68,"profit":false},{"date":"2021-04-30","value":-5.7,"profit":false},{"date":"2022-04-30","value":-14,"profit":false},{"date":"2023-04-30","value":-15,"profit":false},{"date":"2024-04-30","value":-1421,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ALZN | |
---|---|
Cash Ratio | 3.26 |
Current Ratio | 3.80 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ALZN | |
---|---|
ROA (LTM) | -214.47% |
ROE (LTM) | -4408.31% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ALZN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.25 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ALZN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.72 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Alzamend Neuro Inc (ALZN) share price today is $1.22
Yes, Indians can buy shares of Alzamend Neuro Inc (ALZN) on Vested. To buy Alzamend Neuro Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALZN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Alzamend Neuro Inc (ALZN) via the Vested app. You can start investing in Alzamend Neuro Inc (ALZN) with a minimum investment of $1.
You can invest in shares of Alzamend Neuro Inc (ALZN) via Vested in three simple steps:
The 52-week high price of Alzamend Neuro Inc (ALZN) is $12.9. The 52-week low price of Alzamend Neuro Inc (ALZN) is $1.06.
The price-to-earnings (P/E) ratio of Alzamend Neuro Inc (ALZN) is
The price-to-book (P/B) ratio of Alzamend Neuro Inc (ALZN) is 1.72
The dividend yield of Alzamend Neuro Inc (ALZN) is 0.00%
The market capitalization of Alzamend Neuro Inc (ALZN) is $6.47M
The stock symbol (or ticker) of Alzamend Neuro Inc is ALZN